Table 2

Summary of scheduled assessment and follow-up during the study

EvaluationsVisit 0Visit 1–8Visit 9Visit 10Visit 11Visit 12Visit 13
DischargeMonth:
0–6 after discharge
Month:
12 after discharge
Month:
18 after discharge
Month:
24 after discharge
Month:
30 after discharge
Month:
36 after discharge
Informed consentX
Inclusion/exclusion criteriaX
RandomisationX
Demographic dataX
Clinical dataX
Blood sampleXX
BMIXXX
SarcopeniaXXX
Haematological indicatorsXXX
QoL (EORTC QLQ-C30)XXX
ω-3 PUFAs intakes in dietXX
Chemotherapy toleranceX
Chemotherapy toxicityX
Adherence to interventionsX
Adverse eventsX
Unplanned readmissionX
CT or MRIXXXXXX
Tumour markersXXXXXX
EndoscopyXXX
DFSX
OSX
  • BMI, body mass index; DFS, disease-free survival; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; OS, overall survival; QoL, quality of life.